medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/ms2025-183medsovet-9100Research ArticleДРУГИЕ ПРОБЛЕМЫ ЭНДОКРИНОЛОГИИOTHER PROBLEMS OF ENDOCRINOLOGYЗа пределами ИМТ: обсуждаем новую концепцию определения и диагностики клинического ожиренияBeyond BMI: We are discussing a new concept for the definition and diagnosis of clinical obesityhttps://orcid.org/0000-0001-6385-540XДемидоваТ. Ю.DemidovaT. Yu.

Демидова Татьяна Юльевна, д.м.н., профессор, заведующая кафедрой эндокринологии института клинической медицины

117997, Россия, Москва, ул. Островитянова, д. 1

Tatiana Yu. Demidova, Dr. Sci. (Med.), Professor, Head of Department of Endocrinology, Institute of Clinical Medicine

1, Ostrovityanov St., Moscow, 117997, Russia

t.y.demidova@gmail.comhttps://orcid.org/0000-0002-2028-8748КислякО. А.KislyakO. A.

Кисляк Оксана Андреевна, д.м.н., профессор кафедры факультетской терапии института клинической медицины

117997, Россия, Москва, ул. Островитянова, д. 1

Oksana A. Kislyak, Dr. Sci. (Med.), Professor of the Intermediate Level Therapy Department, Institute of Clinical Medicine

1, Ostrovityanov St., Moscow, 117997, Russia

https://orcid.org/0000-0001-9262-9233СтародубоваА. В.StarodubovaA. V.

Стародубова Антонина Владимировна, д.м.н., профессор, заведующая кафедрой факультетской терапии института клинической медицины

117997, Россия, Москва, ул. Островитянова, д. 1

Antonina V. Starodubova, Dr. Sci. (Med.), Professor, Head of Intermediate Level Therapy Department, Institute of Clinical Medicine

1, Ostrovityanov St., Moscow, 117997, Russia

https://orcid.org/0000-0003-1699-0881НикитинИ. Г.NikitinI. G.

Никитин Игорь Геннадиевич, д.м.н., профессор, заведующий кафедрой госпитальной терапии имени академика Г.И. Сторожакова института клинической медицины

117997, Россия, Москва, ул. Островитянова, д. 1

Igor G. Nikitin, Dr. Sci. (Med.), Professor, Head of Department of Hospital Therapy named after Academician G.I. Storozhakov, Institute of Clinical Medicine

1, Ostrovityanov St., Moscow, 117997, Russia

igor.nikitin.64@mail.ruhttps://orcid.org/0000-0001-5512-6899УшановаФ. О.UshanovaF. O.

Ушанова Фатима Омариевна, к.м.н., доцент кафедры эндокринологии института клинической медицины

117997, Россия, Москва, ул. Островитянова, д. 1

Fatima O. Ushanova, Cand. Sci. (Med.), Associate Professor of the Department of Endocrinology, Institute of Clinical Medicine

1, Ostrovityanov St., Moscow, 117997, Russia

fati_2526@mail.ruРоссийский национальный исследовательский медицинский университет имени Н.И. ПироговаРоссияPirogov Russian National Research Medical UniversityRussian Federation202524052025068698Copyright © Демидова Т.Ю., Кисляк О.А., Стародубова А.В., Никитин И.Г., Ушанова Ф.О., 20252025Демидова Т.Ю., Кисляк О.А., Стародубова А.В., Никитин И.Г., Ушанова Ф.О.Demidova T.Y., Kislyak O.A., Starodubova A.V., Nikitin I.G., Ushanova F.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/9100

Ожирение представляет собой серьезную угрозу здоровью населения во всем мире. Являясь неотъемлемым компонентом неблагоприятного кардиометаболического континуума, ожирение преимущественно рассматривается в роли фактора риска развития ряда неинфекционных заболеваний. В то же время, согласно действующим подходам к его определению, ожирение является самостоятельным заболеванием, приводящим к ухудшению здоровья человека. В связи с этим растущее бремя ожирения, тесно связанного с повышением риска развития целого ряда неинфекционных заболеваний, таких как сердечно-сосудистые заболевания, сахарный диабет 2-го типа, хроническая болезнь почек, метаболически ассоциированная жировая болезнь печени, заболевания опорно-двигательного аппарата, диктует необходимость пересмотра устоявшихся взглядов на эту сложную проблему. В январе 2025 г. была представлена новая концепция «Определение и диагностические критерии клинического ожирения», разработанная комиссией журнала Lancet, состоящей из 56 ведущих клинических экспертов. Авторы призывают переосмыслить понимание ожирения, высказывая аргументы как в пользу, так и против действующего определения ожирения. Предложено разделение на доклиническое и клиническое ожирение с учетом органной дисфункции, обусловленной избыточным весом. Определение клинического ожирения, по мнению авторов, заполняет важный концептуальный пробел в понятии ожирения, поскольку обеспечивает клиническую идентичность характерным изменением функции органов, непосредственно вызванным избыточным ожирением, независимо от других заболеваний, связанных с ним. Такое переосмысление обеспечивает значимый медицинский механизм для информирования о диагностике, принятии клинических и управленческих решений в здравоохранении. В настоящей статье выполнен обзор основных сведений о текущих подходах к диагностике ожирения и принципах новой концепции определения и стадирования ожирения.

Obesity is a serious threat to public health worldwide. Being an integral component of the unfavorable cardiometabolic continuum, obesity is mainly considered as a risk factor for the development of a number of non-communicable diseases. At the same time, according to current approaches to its definition, obesity is an independent disease that leads to a deterioration in human health. In this regard, the growing burden of obesity, which is closely associated with an increased risk of developing a number of non-communicable diseases, such as cardiovascular diseases, type 2 diabetes mellitus, chronic kidney disease, metabolic-associated fatty liver disease, and diseases of the musculoskeletal system, dictates the need to revise established views on this complex problem. In January 2025, a new concept “Definition and diagnostic criteria of clinical obesity” was presented, developed by a Lancet journal commission consisting of 56 leading clinical experts. The authors call for a “rethink of the understanding of obesity, arguing both for and against the current definition of obesity. A division into preclinical and clinical obesity is proposed, taking into account the organ dysfunction caused by overweight. The definition of clinical obesity, according to the authors, fills an important conceptual gap in the concept of obesity, since it provides clinical identity to the characteristic changes in organ function directly caused by overweight, regardless of other diseases associated with it. This rethinking provides a meaningful medical mechanism for informing diagnosis, clinical decision-making, and management decisions in healthcare. This article provides an overview of the basic information about current approaches to the diagnosis of obesity and the principles of a new concept for the definition and staging of obesity.

клиническое ожирениеиндекс массы телажировая тканьизбыточный весметаболический синдромкардиометаболическое здоровьеclinical obesitybody mass indexadipose tissueoverweightmetabolic syndromecardiometabolic healthReferencesДедов ИИ, Шестакова МВ, Мельниченко ГА, Мазурина НВ, Андреева ЕН, Бондаренко ИЗ и др. Междисциплинарные клинические рекомендации «Лечение ожирения и коморбидных заболеваний». Ожирение и метаболизм. 2021;18(1):5–99. https://doi.org/10.14341/omet12714.Dedov II, Shestakova MV, Melnichenko GA, Mazurina NV, Andreeva EN, Bondarenko IZ et al. Interdisciplinary clinical practice guidelines “management of obesity and its comorbidities”. Obesity and Metabolism. 2021;18(1):5–99. (In Russ.) https://doi.org/10.14341/omet12714.Борьба с ожирением как фокус развития здравоохранения. Ожирение и метаболизм. 2022;19(1):4–6. https://doi.org/10.14341/omet12865.Fighting obesity as a direction of national health care development. Obesity and Metabolism. 2022;19(1):4–6. (In Russ.) https://doi.org/10.14341/omet12865.NCD Risk Factor Collaboration (NCD-risc) Worldwide trends in underweight and obesity from 1990 to 2022: A pooled analysis of 3663 populationrepresentative studies with 222 million children, adolescents, and adults. Lancet. 2024;403(10431):1027–1050. https://doi.org/10.1016/S0140-6736(23)02750-2.NCD Risk Factor Collaboration (NCD-risc) Worldwide trends in underweight and obesity from 1990 to 2022: A pooled analysis of 3663 populationrepresentative studies with 222 million children, adolescents, and adults. Lancet. 2024;403(10431):1027–1050. https://doi.org/10.1016/S0140-6736(23)02750-2.Деев ИА, Кобякова ОС, Стародубов ВИ, Александрова ГА, Голубев НА, Оськов ЮИ и др. Заболеваемость всего населения России в 2023 году. М.: ФГБУ «ЦНИИОИЗ» Минздрава России; 2024. 154 с. Режим доступа: https://www.niig.su/images/documents/sgm/regions/02_Общая_заболеваемость_всего_населения_России_в_2023_году.pdf.Деев ИА, Кобякова ОС, Стародубов ВИ, Александрова ГА, Голубев НА, Оськов ЮИ и др. Заболеваемость всего населения России в 2023 году. М.: ФГБУ «ЦНИИОИЗ» Минздрава России; 2024. 154 с. Режим доступа: https://clck.ru/3M9F3m.Титова ВВ, Ушанова ФО, Демидова ТЮ. Медикаментозная терапия ожирения: современные подходы и перспективы. FOCUS Эндокринология. 2024;5(4):40–48. https://doi.org/10.62751/2713-0177-2024-5-4-18.Titova VV, Ushanova FO, Demidova TYu. Medical treatment of obesity: Modern approaches and prospects. FOCUS. Endocrinology. 2024;5(4):40–48. (In Russ.) https://doi.org/10.62751/2713-0177-2024-5-4-18.Мустафина СВ, Винтер ДА, Алферова ВИ. Влияние ожирения на формирование и развитие рака. Ожирение и метаболизм. 2024;21(2):205–214. https://doi.org/10.14341/omet13025.Mustafina SV, Vinter DA, Alferova VI. Influence of obesity on the formation and development of cancer. Obesity and Metabolism. 2024;21(2):205–214. (In Russ.) https://doi.org/10.14341/omet13025.Mohajer N, Du CY, Checkcinco C, Blumberg B. Obesogens: How They Are Identified and Molecular Mechanisms Underlying Their Action. Front Endocrinol. 2021;12:780888. https://doi.org/10.3389/fendo.2021.780888.Mohajer N, Du CY, Checkcinco C, Blumberg B. Obesogens: How They Are Identified and Molecular Mechanisms Underlying Their Action. Front Endocrinol. 2021;12:780888. https://doi.org/10.3389/fendo.2021.780888.Loos RJF, Yeo GSH. The genetics of obesity: from discovery to biology. Nat Rev Genet. 2022;23(2):120–133. https://doi.org/10.1038/s41576-021-00414-z.Loos RJF, Yeo GSH. The genetics of obesity: from discovery to biology. Nat Rev Genet. 2022;23(2):120–133. https://doi.org/10.1038/s41576-021-00414-z.Farooqi SI. Genetic, molecular and physiological mechanisms involved in human obesity: Society for Endocrinology Medal Lecture 2012. Clin Endocrinol. 2015;82(1):23–28. https://doi.org/10.1111/cen.12588.Farooqi SI. Genetic, molecular and physiological mechanisms involved in human obesity: Society for Endocrinology Medal Lecture 2012. Clin Endocrinol. 2015;82(1):23–28. https://doi.org/10.1111/cen.12588.Chait A, den Hartigh LJ. Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease. Front Cardiovasc Med. 2020;7:22. https://doi.org/10.3389/fcvm.2020.00022.Chait A, den Hartigh LJ. Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease. Front Cardiovasc Med. 2020;7:22. https://doi.org/10.3389/fcvm.2020.00022.Rimbach R, Yamada Y, Sagayama H, Ainslie PN, Anderson LF, Anderson LJ, et al. Total energy expenditure is repeatable in adults but not associated with short-term changes in body composition. Nat Commun. 2022;13(1):99. https://doi.org/10.1038/s41467-021-27246-z.Rimbach R, Yamada Y, Sagayama H, Ainslie PN, Anderson LF, Anderson LJ, et al. Total energy expenditure is repeatable in adults but not associated with short-term changes in body composition. Nat Commun. 2022;13(1):99. https://doi.org/10.1038/s41467-021-27246-z.Bray GA. Beyond BMI. Nutrients. 2023;15(10):2254. https://doi.org/10.3390/nu15102254.Bray GA. Beyond BMI. Nutrients. 2023;15(10):2254. https://doi.org/10.3390/nu15102254.Després JP. BMI versus obesity subtypes in the era of precision medicine. Lancet Diabetes Endocrinol. 2023;11(6):382–384. https://doi.org/10.1016/S2213-8587(23)00088-8.Després JP. BMI versus obesity subtypes in the era of precision medicine. Lancet Diabetes Endocrinol. 2023;11(6):382–384. https://doi.org/10.1016/S2213-8587(23)00088-8.Mechanick JI, Hurley DL, Garvey WT. Adiposity-based chronic disease as a new diagnostic term: the american association of clinical endocrinologists and american college of endocrinology position statement. Endocr Pract. 2017;23(3):372–378. https://doi.org/10.4158/EP161688.PS.Mechanick JI, Hurley DL, Garvey WT. Adiposity-based chronic disease as a new diagnostic term: the american association of clinical endocrinologists and american college of endocrinology position statement. Endocr Pract. 2017;23(3):372–378. https://doi.org/10.4158/EP161688.PS.Frühbeck G, Busetto L, Dicker D, Yumuk V, Goossens GH, Hebebrand J et al. The ABCD of Obesity: An EASO Position Statement on a Diagnostic Term with Clinical and Scientific Implications. Obes Facts. 2019;12(2):131–136. https://doi.org/10.1159/000497124.Frühbeck G, Busetto L, Dicker D, Yumuk V, Goossens GH, Hebebrand J et al. The ABCD of Obesity: An EASO Position Statement on a Diagnostic Term with Clinical and Scientific Implications. Obes Facts. 2019;12(2):131–136. https://doi.org/10.1159/000497124.Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, Sowers MR. he obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med. 2008;168(15):1617–1624. https://doi.org/10.1001/archinte.168.15.1617.Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, Sowers MR. he obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med. 2008;168(15):1617–1624. https://doi.org/10.1001/archinte.168.15.1617.Sinaga M, Worku M, Yemane T, Tegene E, Wakayo T, Girma T et al. Optimal cut-off for obesity and markers of metabolic syndrome for Ethiopian adults. Nutr J. 2018;17(1):109. https://doi.org/10.1186/s12937-018-0416-0.Sinaga M, Worku M, Yemane T, Tegene E, Wakayo T, Girma T et al. Optimal cut-off for obesity and markers of metabolic syndrome for Ethiopian adults. Nutr J. 2018;17(1):109. https://doi.org/10.1186/s12937-018-0416-0.Rubino F, Cummings DE, Eckel RH, Cohen RV, Wilding JPH, Brown WA et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13(3):221–262. https://doi.org/10.1016/S2213-8587(24)00316-4.Rubino F, Cummings DE, Eckel RH, Cohen RV, Wilding JPH, Brown WA et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13(3):221–262. https://doi.org/10.1016/S2213-8587(24)00316-4.Eisenberg D, Shikora SA, Aarts E, Aminian A, Angrisani L, Cohen RV et al. 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery. Obes Surg. 2023;33(1):3–14. https://doi.org/10.1007/s11695-022-06332-1.Eisenberg D, Shikora SA, Aarts E, Aminian A, Angrisani L, Cohen RV et al. 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery. Obes Surg. 2023;33(1):3–14. https://doi.org/10.1007/s11695-022-06332-1.Martin S, Tyrrell J, Thomas EL, Bown MJ, Wood AR, Beaumont RN, et al. Disease consequences of higher adiposity uncoupled from its adverse metabolic effects using Mendelian randomisation. Elife. 2022;11:e72452. https://doi.org/10.7554/eLife.72452.Martin S, Tyrrell J, Thomas EL, Bown MJ, Wood AR, Beaumont RN, et al. Disease consequences of higher adiposity uncoupled from its adverse metabolic effects using Mendelian randomisation. Elife. 2022;11:e72452. https://doi.org/10.7554/eLife.72452.Wang MTM, Bhatti MT, Danesh-Meyer HV. Idiopathic intracranial hypertension: Pathophysiology, diagnosis and management. J Clin Neurosci. 2022;95:172–179. https://doi.org/10.1016/j.jocn.2021.11.029.Wang MTM, Bhatti MT, Danesh-Meyer HV. Idiopathic intracranial hypertension: Pathophysiology, diagnosis and management. J Clin Neurosci. 2022;95:172–179. https://doi.org/10.1016/j.jocn.2021.11.029.Seetho IW, Wilding JP. Sleep-disordered breathing, type 2 diabetes and the metabolic syndrome. Chron Respir Dis. 2014;11(4):257–275. https://doi.org/10.1177/1479972314552806.Seetho IW, Wilding JP. Sleep-disordered breathing, type 2 diabetes and the metabolic syndrome. Chron Respir Dis. 2014;11(4):257–275. https://doi.org/10.1177/1479972314552806.Dixon AE, Peters U. The effect of obesity on lung function. Expert Rev Respir Med. 2018;12(9):755–767. https://doi.org/10.1080/17476348.2018.1506331.Dixon AE, Peters U. The effect of obesity on lung function. Expert Rev Respir Med. 2018;12(9):755–767. https://doi.org/10.1080/17476348.2018.1506331.Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res. 2023;118(18):3434–3450. https://doi.org/10.1093/cvr/cvac120.Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res. 2023;118(18):3434–3450. https://doi.org/10.1093/cvr/cvac120.Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389(12):1069–1084. https://doi.org/10.1056/NEJMoa2306963.Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389(12):1069–1084. https://doi.org/10.1056/NEJMoa2306963.Pontiroli AE, Centofanti L, Le Roux CW, Magnani S, Tagliabue E, Folli F. Effect of Prolonged and Substantial Weight Loss on Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis. Nutrients. 2023;15(4):940. https://doi.org/10.3390/nu15040940.Pontiroli AE, Centofanti L, Le Roux CW, Magnani S, Tagliabue E, Folli F. Effect of Prolonged and Substantial Weight Loss on Incident Atrial Fibrillation: A Systematic Review and Meta-Analysis. Nutrients. 2023;15(4):940. https://doi.org/10.3390/nu15040940.Sattar N, Deanfield J, Delles C. Impact of intentional weight loss in cardiometabolic disease: what we know about timing of benefits on differing outcomes? Cardiovasc Res. 2024;119(18):e167–e171. https://doi.org/10.1093/cvr/cvac186.Sattar N, Deanfield J, Delles C. Impact of intentional weight loss in cardiometabolic disease: what we know about timing of benefits on differing outcomes? Cardiovasc Res. 2024;119(18):e167–e171. https://doi.org/10.1093/cvr/cvac186.Lazarus JV, Newsome PN, Francque SM, Kanwal F, Terrault NA, Rinella ME. Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2024;79(3):E93–E94. https://doi.org/10.1097/HEP.0000000000000696.Lazarus JV, Newsome PN, Francque SM, Kanwal F, Terrault NA, Rinella ME. Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2024;79(3):E93–E94. https://doi.org/10.1097/HEP.0000000000000696.Nawaz S, Chinnadurai R, Al-Chalabi S, Evans P, Kalra PA, Syed AA, Sinha S. Obesity and chronic kidney disease: A current review. Obes Sci Pract. 2022;9(2):61–74. https://doi.org/10.1002/osp4.629.Nawaz S, Chinnadurai R, Al-Chalabi S, Evans P, Kalra PA, Syed AA, Sinha S. Obesity and chronic kidney disease: A current review. Obes Sci Pract. 2022;9(2):61–74. https://doi.org/10.1002/osp4.629.Doumouchtsis SK, Loganathan J, Pergialiotis V. The role of obesity on urinary incontinence and anal incontinence in women: a review. BJOG. 2022;129(1):162–170. https://doi.org/10.1111/1471-0528.16848.Doumouchtsis SK, Loganathan J, Pergialiotis V. The role of obesity on urinary incontinence and anal incontinence in women: a review. BJOG. 2022;129(1):162–170. https://doi.org/10.1111/1471-0528.16848.Armanini D, Boscaro M, Bordin L, Sabbadin C. Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism. Int J Mol Sci. 2022;23(8):4110. https://doi.org/10.3390/ijms23084110.Armanini D, Boscaro M, Bordin L, Sabbadin C. Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism. Int J Mol Sci. 2022;23(8):4110. https://doi.org/10.3390/ijms23084110.Sultan S, Patel AG, El-Hassani S, Whitelaw B, Leca BM, Vincent RP et al. Male Obesity Associated Gonadal Dysfunction and the Role of Bariatric Surgery. Front Endocrinol. 2020;11:408. https://doi.org/10.3389/fendo.2020.00408.Sultan S, Patel AG, El-Hassani S, Whitelaw B, Leca BM, Vincent RP et al. Male Obesity Associated Gonadal Dysfunction and the Role of Bariatric Surgery. Front Endocrinol. 2020;11:408. https://doi.org/10.3389/fendo.2020.00408.Urban H, Little CB. The role of fat and inflammation in the pathogenesis and management of osteoarthritis. Rheumatology. 2018;57(Suppl. 4):iv10–iv21. https://doi.org/10.1093/rheumatology/kex399.Urban H, Little CB. The role of fat and inflammation in the pathogenesis and management of osteoarthritis. Rheumatology. 2018;57(Suppl. 4):iv10–iv21. https://doi.org/10.1093/rheumatology/kex399.Ernst AM, Bauer H, Bauer HC, Steiner M, Malfertheiner A, Lipp AT. Lipedema Research-Quo Vadis? J Pers Med. 2022;13(1):98. https://doi.org/10.3390/jpm13010098.Ernst AM, Bauer H, Bauer HC, Steiner M, Malfertheiner A, Lipp AT. Lipedema Research-Quo Vadis? J Pers Med. 2022;13(1):98. https://doi.org/10.3390/jpm13010098.Tareque MI, Saito Y, Chan A, Visaria A, Ma S, Malhotra R. Years of life with and without limitation in physical function and in activities of daily living by body mass index among older adults. Int J Obes. 2019;43(11):2244–2253. https://doi.org/10.1038/s41366-019-0370-8.Tareque MI, Saito Y, Chan A, Visaria A, Ma S, Malhotra R. Years of life with and without limitation in physical function and in activities of daily living by body mass index among older adults. Int J Obes. 2019;43(11):2244–2253. https://doi.org/10.1038/s41366-019-0370-8.Носков СМ, Арефьева АН, Банко ВВ, Радаева КС, Гефен МЛ, Арчакова ОА и др. Препарат семаглутида для лечения ожирения: результаты двух открытых рандомизированных исследований фармакокинетики. Медицинский совет. 2024;18(16):216–222. https://doi.org/10.21518/ms2024-346.Noskov SM, Arefeva AN, Banko VV, Radaeva КS, Gefen ML, Archakova OA et al. Semaglutide for the treatment of obesity: Results of two open randomized pharmacokinetic studies. Meditsinskiy Sovet. 2024;18(16):216–222. (In Russ.) https://doi.org/10.21518/ms2024-346.

The authors declare that there are no conflicts of interest present.